News

The industry-wide shift towards RBx is not only reducing risk, but improving oversight and boosting proactive, predictive decision making, writes Cluepoints' CCO, Patrick Hughes.

Dave Li explores the current information on the commercialization of advanced therapy medicinal products.

The latest happenings of the past month in the industry, all in one place.

Clinical research must deploy innovative, disruptive approaches without disrupting patients.

Findings from analyzed data from approximately 300 web survey responses representing over 200 global individual sponsor and provider organizations

Peter O'Donnell discusses the outpouring of support for Stella Kyriakides, who has been designated to lead European Union health policy for the next five years, and how she might need every bit of it.